Peripheral Neuropathy Trial, Recruiting NCT07300163 Sponsor: Diabetis JSC Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT07300163
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older, of any sex
  • People who have been diagnosed with either type 1 or type 2 diabetes
  • People who have had one or more diabetic foot ulcers on the sole of the foot in the past
  • People whose foot ulcer has fully healed for at least 6 weeks before joining, as confirmed by a specialist healthcare provider
  • People who have diabetic nerve damage in their feet, shown by being unable to feel a soft touch test (using a 10g monofilament) at two points on the foot, or by having a reduced ability to feel vibration above a certain level (confirm with trial site)
  • People who have at least one detectable pulse in the foot

Who may not be able to join:

  • People who currently have an open or active foot ulcer
  • People who have an active condition called Charcot neuro-osteoarthropathy, which is a type of serious bone and joint problem in the foot related to nerve damage
  • People with severe blood vessel disease, meaning no foot pulses can be detected at all
  • People who have had an amputation of the lower limb or foot beyond the base of the toe joints
  • People who currently have an active cancer or a condition that affects the immune system
  • People whose physical or mental health condition makes it difficult to follow the study instructions without assistance, as assessed by their doctor
  • People who are currently taking part in another clinical trial involving a medical device that conflicts with this study's procedures or outcomes

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Neil Reeves, Prof, Phd, Manchester University NHS Foundation Trust (MFT)

Phone: +31615636666

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Diabetis JSC
Registry
ClinicalTrials.gov
Start date
16 December 2025
Est. completion
30 May 2027

Where this trial is recruiting

🇱🇹 Lithuania 🇬🇧 United Kingdom

Primary endpoints

DFU occurrence over the six to nine-month follow-up period.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov